

Lucia Gabriele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3105855/publications.pdf>

Version: 2024-02-01

69
papers

5,627
citations

126907

33
h-index

98798

67
g-index

73
all docs

73
docs citations

73
times ranked

8706
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	4.6	686
2	Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene. <i>Cell</i> , 1996, 87, 307-317.	28.9	615
3	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
4	ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8 ⁺ Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1415-1425.	8.5	389
5	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. <i>Cancer Research</i> , 2011, 71, 768-778.	0.9	304
6	The Feedback Phase of Type I Interferon Induction in Dendritic Cells Requires Interferon Regulatory Factor 8. <i>Immunity</i> , 2007, 27, 228-239.	14.3	154
7	Interferon (IFN) Consensus Sequence-binding Protein, a Transcription Factor of the IFN Regulatory Factor Family, Regulates Immune Responses In Vivo through Control of Interleukin 12 Expression. <i>Journal of Experimental Medicine</i> , 1997, 186, 1535-1546.	8.5	153
8	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. <i>Scientific Reports</i> , 2017, 7, 1093.	3.3	130
9	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. <i>Lab on A Chip</i> , 2013, 13, 229-239.	6.0	126
10	The Tumor Microenvironment: A Pitch for Multiple Players. <i>Frontiers in Oncology</i> , 2013, 3, 90.	2.8	121
11	Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. <i>Frontiers in Immunology</i> , 2013, 4, 483.	4.8	113
12	Type I IFNs Control Antigen Retention and Survival of CD8 ⁺ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. <i>Journal of Immunology</i> , 2011, 186, 5142-5150.	0.8	110
13	A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 11295-11300.	7.1	106
14	Regulation of Apoptosis in Myeloid Cells by Interferon Consensus Sequence- α -Binding Protein. <i>Journal of Experimental Medicine</i> , 1999, 190, 411-422.	8.5	104
15	ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. <i>Blood</i> , 2004, 103, 2221-2228.	1.4	98
16	Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. <i>Molecular and Cellular Neurosciences</i> , 2010, 45, 234-244.	2.2	93
17	Interleukin (IL)-4-independent immunoglobulin class switch to immunoglobulin (Ig)E in the mouse.. <i>Journal of Experimental Medicine</i> , 1996, 184, 1651-1661.	8.5	81
18	IFN Regulatory Factor-1 Negatively Regulates CD4 ⁺ CD25 ⁺ Regulatory T Cell Differentiation by Repressing Foxp3 Expression. <i>Journal of Immunology</i> , 2008, 181, 1673-1682.	0.8	76

#	ARTICLE	IF	CITATIONS
19	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	4.8	74
20	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 432.	8.6	74
21	Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. <i>Cancers</i> , 2019, 11, 1943.	3.7	73
22	Sex disparity in cancer: roles of microRNAs and related functional players. <i>Cell Death and Differentiation</i> , 2018, 25, 477-485.	11.2	71
23	LOX-1 as a natural IFN- γ -mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. <i>Blood</i> , 2010, 115, 1554-1563.	1.4	70
24	IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFN γ -responsive promoters in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 91-96.	7.1	69
25	The role of the interferon regulatory factor (IRF) family in dendritic cell development and function. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 503-510.	7.2	69
26	IFN- γ promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. <i>Blood</i> , 2004, 103, 980-987.	1.4	68
27	Cancer-driven dynamics of immune cells in a microfluidic environment. <i>Scientific Reports</i> , 2014, 4, 6639.	3.3	68
28	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. <i>Oncotarget</i> , 2017, 8, 77110-77120.	1.8	59
29	IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1500-1511.	3.3	50
30	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. <i>Neoplasia</i> , 2012, 14, 1223-IN43.	5.3	48
31	A multidisciplinary study using <i>in vivo</i> tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <i>Journal of Immunotoxicology</i> , 2014, 11, 337-346.	1.7	48
32	Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon- γ and Herpes Simplex Thymidine Kinase Followed by Ganciclovir. <i>Human Gene Therapy</i> , 1996, 7, 1-10.	2.7	43
33	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4320.	4.1	43
34	Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. <i>Leukemia</i> , 2004, 18, 1864-1871.	7.2	42
35	The Natural Agonist of Estrogen Receptor β Silibinin Plays an Immunosuppressive Role Representing a Potential Therapeutic Tool in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 1903.	4.8	39
36	Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases. <i>Journal of Experimental Medicine</i> , 1991, 173, 313-322.	8.5	35

#	ARTICLE	IF	CITATIONS
37	Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. <i>British Journal of Pharmacology</i> , 2017, 174, 139-149.	5.4	34
38	Tumor-on-a-chip platforms to study cancer-immune system crosstalk in the era of immunotherapy. <i>Lab on A Chip</i> , 2021, 21, 234-253.	6.0	34
39	Apicidin and Docetaxel Combination Treatment Drives CTCFL Expression and HMGB1 Release Acting as Potential Antitumor Immune Response Inducers in Metastatic Breast Cancer Cells. <i>Neoplasia</i> , 2012, 14, 855-IN19.	5.3	31
40	The gender perspective in cancer research and therapy: novel insights and on-going hypotheses. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2016, 52, 213-22.	0.4	30
41	Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes. <i>Journal of Cellular Physiology</i> , 2019, 234, 20453-20468.	4.1	29
42	Anti-IFN- γ neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. <i>European Journal of Immunology</i> , 2022, 52, 1120-1128.	2.9	29
43	Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2019, 469, 1-10.	1.4	28
44	Antitumor Effects of Epidrug/IFN- γ Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells. <i>Cancer Immunology Research</i> , 2017, 5, 604-616.	3.4	27
45	IFN- γ Regulates Blimp-1 Expression via miR-23a and miR-125b in Both Monocytes-Derived DC and pDC. <i>PLoS ONE</i> , 2013, 8, e72833.	2.5	26
46	ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4 ⁺ T cells. <i>Blood</i> , 2006, 108, 609-617.	1.4	25
47	IFN- γ potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 26361-26373.	1.8	25
48	Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 686-695.e7.	2.9	22
49	Mycobacterium tuberculosis PstS amplifies IFN- γ and induces IL-17 and IL-22 responses by unrelated memory CD4 ⁺ T cells via dendritic cell activation. <i>European Journal of Immunology</i> , 2013, 43, 2386-2397.	2.9	21
50	New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 137.	8.6	21
51	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. <i>Nanoscale</i> , 2016, 8, 7562-7571.	5.6	15
52	IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. <i>Vaccines</i> , 2020, 8, 617.	4.4	14
53	Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 66-74.	7.2	14
54	Impaired IFN- γ -mediated signal in dendritic cells differentiates active from latent tuberculosis. <i>PLoS ONE</i> , 2018, 13, e0189477.	2.5	11

#	ARTICLE	IF	CITATIONS
55	The use of microarray technologies in clinical oncology. <i>Journal of Translational Medicine</i> , 2006, 4, 8.	4.4	10
56	Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 582744.	4.8	9
57	Autoantibodies Specific to ER α are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. <i>Cells</i> , 2019, 8, 750.	4.1	8
58	Relationship of cytokines and cytokine signaling to immunodeficiency disorders in the mouse. <i>Brazilian Journal of Medical and Biological Research</i> , 1998, 31, 61-67.	1.5	7
59	The dual role of IRF8 in cancer immunosurveillance. <i>Oncotarget</i> , 2013, 2, e25476.	4.6	7
60	Dendritic cells modulate c α expression on the edge between activation and death. <i>European Journal of Immunology</i> , 2019, 49, 534-545.	2.9	7
61	Interferon Regulatory Factor 8-Deficiency Determines Massive Neutrophil Recruitment but T Cell Defect in Fast Growing Granulomas during Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e62751.	2.5	6
62	Synergistic anti-tumor effects of combined IL-1/IFN- γ /IFN- β therapy in mice injected with metastatic friend erythroleukemia cells. <i>International Journal of Cancer</i> , 1991, 49, 274-278.	5.1	5
63	ER α stimulation attenuates melanoma growth in mice. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	5
64	Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 685.	2.5	5
65	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 363.	3.6	4
66	Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host. <i>International Journal of Cancer</i> , 1995, 62, 184-190.	5.1	2
67	Microarray Analysis for Monitoring the Response to Interferon. <i>Journal of Immunotherapy</i> , 2005, 28, 619-620.	2.4	2
68	Abstract 1656: CXCR4 antagonist-expressing liposomes reduce lung metastases and deliver drugs to CXCR4 expressing cells: a new drug-targeting device. , 2014, , .		0
69	Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors. <i>Cell & Gene Therapy Insights</i> , 2020, 6, 1231-1236.	0.1	0